Amgen Shares Acquired by Lbp Am Sa

Institutional investor boosts stake in biotech giant Amgen by over 100%

Apr. 16, 2026 at 10:35am

Got story updates? Submit your updates here. ›

An extreme close-up of a tangle of industrial gears and machinery, representing the intricate inner workings of a major biotech company like Amgen.Institutional investors are betting big on the complex, high-tech machinery powering Amgen's pharmaceutical innovation.Thousand Oaks Today

Lbp Am Sa, an institutional investor, increased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 108.1% in the 4th quarter, according to a recent SEC filing. The fund now owns 51,776 shares of the medical research company's stock, valued at $16.9 million.

Why it matters

This significant increase in Lbp Am Sa's Amgen holdings suggests the institutional investor sees strong potential in the biotech company's future performance and growth prospects. Amgen is a major player in the pharmaceutical industry, known for its innovative biologic medicines.

The details

According to the SEC filing, Lbp Am Sa purchased an additional 26,897 shares of Amgen during the fourth quarter, bringing its total position to 51,776 shares. This marks a 108.1% increase in the fund's Amgen holdings compared to the prior quarter. Amgen is a large-cap biotech firm focused on developing and commercializing human therapeutics to address serious illnesses.

  • Lbp Am Sa increased its Amgen holdings in the 4th quarter of 2025.

The players

Lbp Am Sa

An institutional investor that manages a portfolio of stocks, including a significant position in pharmaceutical company Amgen Inc.

Amgen Inc.

A global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. Amgen focuses on discovering, developing, manufacturing, and delivering human therapeutics to address serious illnesses.

Got photos? Submit your photos here. ›

The takeaway

This increase in institutional investment in Amgen suggests Wall Street's confidence in the company's long-term growth potential, as it continues to develop innovative biologic medicines to address unmet medical needs.